A Plain-English Look at a Proposed “Ketamine-Like” Antidepressant Strategy

Source article: Ngo Cheung, “DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs,” Frontiers in Psychiatry 17:1751605, 2026. https://doi.org/10.3389/fpsyt.2026.1751605

Key background reading: Ketamine’s rapid antidepressant effects have been linked to glutamate signaling, AMPA receptor activation, BDNF, mTOR, and new synaptic growth.[1–6] The prescription drug Auvelity combines dextromethorphan and bupropion and is already used for major depressive disorder.[7,15]

Can Ordinary Medicines Imitate Part of Ketamine’s Antidepressant Effect?

For decades, depression treatment has often been explained through the “chemical imbalance” story: serotonin, dopamine, norepinephrine, and so on. That story is not useless, but it is incomplete. Many people know the frustrating reality: a standard antidepressant may take four to six weeks to work, and sometimes it barely works at all.

Ketamine changed the conversation. In some patients with severe depression, ketamine can lift mood within hours or days, not weeks.[2] That is a big deal. It suggests that depression is not only about “low serotonin.” It may also involve damaged or underactive brain circuits that can sometimes be restarted quickly.

The paper discussed here proposes a bold but still unproven idea: could a fully oral combination of existing substances push the brain in a ketamine-like direction, without using IV ketamine?

The proposed combination includes:

1. Dextromethorphan, often known as DXM, a cough-medicine ingredient that also affects NMDA receptors.
2. A CYP2D6-inhibiting antidepressant, such as fluoxetine, paroxetine, or duloxetine, to slow DXM breakdown.
3. Piracetam, a nootropic compound thought to influence AMPA-related signaling.
4. L-glutamine, a common amino acid that may support the brain’s glutamate supply.

This is not a proven treatment plan. It is a scientific hypothesis. The important question is not “Does this sound clever?” but “Will it actually work safely in controlled studies?”

The Brain as a City: Brakes, Green Lights, and Repair Crews

To understand the idea, imagine the brain as a busy city.

Some roads are too quiet. Some traffic lights are stuck. Some neighborhoods have lost connections after years of stress. Depression, in this metaphor, is not simply a shortage of fuel. It may also be a traffic-system problem.

Two important “traffic signals” in this system are:

• NMDA receptors, which can act like heavy control gates.
• AMPA receptors, which are more like fast green lights that let signals move quickly.

Ketamine appears to temporarily block certain NMDA receptors, especially on inhibitory brain cells — the “brakes.” When those brakes are briefly released, glutamate signaling increases. That glutamate then stimulates AMPA receptors, which may trigger repair pathways involving BDNF and mTOR.[1,4–6]

In plain language: ketamine may not simply “numb” the brain. It may briefly shake the system awake, allowing brain circuits to reconnect.

That reconnection matters. Chronic stress and depression have been associated with loss of synaptic connections — the tiny contact points where brain cells communicate.[1,6] Ketamine’s rapid effect may come from helping those connections regrow or work better.

Where Auvelity Fits In

Auvelity is a prescription antidepressant containing dextromethorphan and bupropion.[7,15]

Dextromethorphan affects NMDA receptors, somewhat overlapping with one part of ketamine’s mechanism. But DXM is normally broken down quickly by a liver enzyme called CYP2D6. Bupropion slows that enzyme, allowing DXM to stay active longer.

A simple analogy: DXM is the message; CYP2D6 is the shredder; bupropion slows the shredder.

The article argues that Auvelity may provide the first “spark” of ketamine-like action — NMDA modulation — but may not fully deliver the later “flame,” meaning stronger AMPA-driven plasticity. That is still a hypothesis, not a settled fact.

Clinical studies show that dextromethorphan-bupropion can help major depressive disorder, but it is not the same thing as ketamine, and it should not be treated as interchangeable with ketamine.[7,15]

Why Add a CYP2D6-Inhibiting Antidepressant?

The proposed regimen replaces bupropion’s CYP2D6-blocking role with other antidepressants that also inhibit CYP2D6.

Examples include:

• Fluoxetine
• Paroxetine
• Duloxetine, usually a more moderate inhibitor

The logic is straightforward: if DXM disappears too quickly, it may not have enough time to affect brain signaling. A CYP2D6 inhibitor can extend its presence.

But this is also where risk enters the room.

CYP2D6 does not metabolize only DXM. It helps process many medicines, including some beta-blockers, opioids, antipsychotics, and other antidepressants. Blocking it can raise drug levels unexpectedly.[8–14] For some people, that could mean side effects. For others, it could be dangerous.

There is also a genetic issue. Some people naturally have low CYP2D6 activity; others break down CYP2D6 drugs very quickly. So the same dose can behave very differently from one person to another.[14]

This is why the idea cannot responsibly be reduced to “just combine these pills.” Biology is messier than that.

Piracetam: Opening the Door Wider?

The next proposed piece is piracetam.

In the article’s model, DXM helps create the “spark,” while piracetam might help AMPA receptors respond more strongly. If NMDA receptors are like gates and AMPA receptors are like fast signal doors, piracetam is imagined as something that helps those doors open more easily.

Some older research suggests piracetam may influence AMPA receptor density or synaptic plasticity, especially in animal or aging-brain studies.[16–18] But the evidence for piracetam as an antidepressant enhancer in humans is far from conclusive.

A good way to say it is this: piracetam is an interesting candidate, not a proven answer.

This distinction matters. The article’s proposal is mechanistically neat, but medicine is full of neat ideas that did not survive proper testing.

Glutamine: Refilling the Pantry

The final proposed ingredient is L-glutamine.

Glutamine is an amino acid involved in the glutamate–glutamine cycle. In the brain, it helps maintain supplies for glutamate signaling. If glutamate is the “working currency” of fast excitatory communication, glutamine is part of the supply chain.

Think of a restaurant kitchen. DXM changes how the stove works. Piracetam may make the serving window more responsive. But if the pantry is empty, nothing much happens. Glutamine is proposed as a way to help refill the pantry.

Animal studies suggest glutamine supplementation may reverse some chronic-stress-related changes in glutamate/glutamine levels and produce antidepressant-like effects.[19,20] Other studies suggest glutamine may also help regulate excessive glutamate activity under inflammatory conditions.[22–24]

However, translating this into human depression treatment is not simple. The brain is not a smoothie recipe. More “precursor” does not automatically mean better mood, and too much excitatory signaling can be harmful.

The Safety Question: The Most Important Part

The article includes a major safety discussion, and for good reason.

Combining DXM with antidepressants that raise serotonin or inhibit CYP2D6 can increase the risk of:

• jitteriness
• tremor
• insomnia
• fast heart rate
• agitation
• mood activation or hypomania
• drug interactions
• serotonin toxicity

Serotonin toxicity is especially important. DXM has serotonergic properties, and when its levels rise because CYP2D6 is blocked, the risk may increase.

This proposed regimen would be especially concerning for people with:

• bipolar I disorder without mood stabilization
• seizure disorders
• use of MAOIs
• multiple serotonergic medications
• complex medication lists
• older age or medical frailty

The article describes early naturalistic clinical experience, but that is not the same as a randomized controlled trial. Case series can generate useful clues, but they can also overestimate benefit and underestimate harm.

So the most responsible takeaway is: this idea deserves careful study, not casual self-experimentation.

What Would Prove or Disprove the Idea?

One useful feature of the proposal is that it makes testable predictions.

If the theory is right, researchers should eventually be able to show that the combination:

• improves depression scores quickly, possibly within days
• changes brain activity patterns linked to AMPA/glutamate signaling
• increases markers related to plasticity, such as BDNF
• performs better than DXM-bupropion alone in controlled trials
• remains safe across different CYP2D6 genetic profiles

If those things do not happen, the theory would need to be revised or abandoned.

That is how good science should work. A hypothesis is not a victory lap. It is an invitation to test.

A Balanced Bottom Line

This paper presents an ambitious idea: using existing oral agents to imitate more of ketamine’s rapid antidepressant pathway. The concept is built around a chain reaction: keep DXM active, reduce NMDA-related “static,” encourage AMPA signaling, and support glutamate cycling.

It is an intriguing model. It is also not yet proven.

For lay readers, the easiest summary is this:

Ketamine may work quickly because it helps stuck brain circuits reconnect. This proposed oral strategy tries to imitate parts of that process using already-known substances. But the combination has not yet been proven safe and effective in rigorous trials, and it should not be attempted without specialist medical supervision.

The idea is worth studying. It is not ready to be treated as established care.

References and Further Reading

1. Duman RS, Aghajanian GK. “Synaptic dysfunction in depression: Potential therapeutic targets.” Science, 2012. https://doi.org/10.1126/science.1222939
2. Berman RM et al. “Antidepressant effects of ketamine in depressed patients.” Biological Psychiatry, 2000. https://doi.org/10.1016/S0006-3223(99)00230-9
3. Zanos P et al. “NMDAR inhibition-independent antidepressant actions of ketamine metabolites.” Nature, 2016. https://doi.org/10.1038/nature17998
4. Maeng S et al. “Cellular mechanisms underlying the antidepressant effects of ketamine: Role of AMPA receptors.” Biological Psychiatry, 2008. https://doi.org/10.1016/j.biopsych.2007.05.028
5. Koike H, Iijima M, Chaki S. “Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models.” Behavioural Brain Research, 2011. https://doi.org/10.1016/j.bbr.2011.05.035
6. Li N et al. “mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.” Science, 2010. https://doi.org/10.1126/science.1190287
7. McCarthy B et al. “Dextromethorphan-bupropion for the treatment of major depressive disorder.” Clinical Psychopharmacology and Neuroscience, 2023. https://doi.org/10.9758/cpn.23.1081
8. Thase ME, Youakim JM, Skuban A. “Efficacy and safety of dextromethorphan-bupropion in major depressive disorder.” American Journal of Psychiatry, 2022.
9. Winblad B. “Piracetam: A review of pharmacological properties and clinical uses.” CNS Drug Reviews, 2005. https://doi.org/10.1111/j.1527-3458.2005.tb00268.x
10. Son H et al. “Glutamine has antidepressive effects through increments of glutamate and glutamine levels and glutamatergic activity in the medial prefrontal cortex.” Neuropharmacology, 2018. https://doi.org/10.1016/j.neuropharm.2018.09.040
11. Cheung N. “DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs.” Frontiers in Psychiatry, 2026. https://doi.org/10.3389/fpsyt.2026.1751605

Reference:
Cheung N. Symptom-Level Precision Neurology in Amyotrophic Lateral Sclerosis (ALS): Linking Microglial Pruning, Mitochondrial Nicotinamide Adenine Dinucleotide (NAD+) Compensation, and Autophagy Failure Across the Aging Spectrum. Cureus. 2026;18(5):e109147. doi:10.7759/cureus.109147
http://doi.org/10.7759/cureus.109147

Most people know amyotrophic lateral sclerosis — ALS, also called Lou Gehrig’s disease — as a devastating illness in which muscles gradually stop working. Over time, walking, speaking, swallowing, and even breathing can become difficult.

That description is true, but it is also incomplete.

ALS does not look exactly the same in every person. One patient may first notice that their hand feels clumsy when buttoning a shirt, turning a key, or opening a jar. Another may begin with slurred speech or trouble swallowing liquids. Someone else may first experience exhaustion, loss of motivation, emotional changes, or worsening memory. In some people, breathing problems appear earlier than expected.

So the obvious question is: how can one disease produce such different stories?

The Cureus article by Cheung proposes a broad hypothesis to explain this variability. Rather than viewing ALS only as motor neurons breaking down, the article frames ALS as a failure of several interacting support systems in the nervous system: immune pruning, energy production, NAD+ compensation, cellular cleanup, aging, and inflammation. The result is a model in which different neural circuits fail at different times, depending on how much stress they are under and how much biological reserve they still have.

A simple way to understand the idea is to imagine a large restaurant.

The Restaurant Analogy

Picture the nervous system as a busy restaurant.

The chefs are the neurons. They prepare the meals, coordinate timing, and keep everything moving. In ALS, the most visibly affected chefs are the motor neurons — the cells that control voluntary movement.

But a restaurant does not survive on chefs alone.

It also needs:

• a steady power supply;
• backup fuel and cooling systems;
• a cleaning crew;
• maintenance staff;
• managers who decide which equipment should stay, be repaired, or be removed.

In the body, these roles are played by mitochondria, NAD+, autophagy systems, microglia, and other cellular processes.

If the restaurant is running well, the dinner rush is manageable. Even if one station gets busy, the rest of the system can compensate. But if the power flickers, the cleaning crew falls behind, backup supplies run low, and managers start removing equipment that still works, the restaurant does not fail all at once. One section may break down first. Then another. Then another.

That is the central idea of the article: ALS may not be a single uniform collapse, but a circuit-by-circuit loss of balance between biological stress and biological reserve.

The Main Hypothesis: Stress Versus Reserve

The article proposes that symptoms appear when destructive pressures outweigh protective capacity in a specific neural circuit.

On the stress side are factors such as:

• excessive microglial pruning;
• excitatory burden, especially involving glutamate;
• chronic inflammation;
• aging-related cellular wear and tear.

On the protective side are systems such as:

• mitochondrial energy production;
• NAD+ buffering capacity;
• autophagy, the cell’s cleanup and recycling system.

When a circuit still has enough reserve, it may function normally or nearly normally. When reserve weakens, symptoms begin. When reserve is overwhelmed, the circuit may collapse.

This helps explain why one person may begin with hand weakness, another with speech problems, and another with cognitive or behavioral changes. Different circuits may be reaching their breaking points at different times.

Microglia: The Managers Who Prune Too Much

Microglia are often described as the immune cells of the brain and spinal cord. They patrol the nervous system, respond to injury, clear debris, and help shape neural connections.

One of their jobs is synaptic pruning. A synapse is a connection point between neurons. Pruning removes unnecessary or damaged synapses so that neural networks remain efficient.

In the restaurant analogy, microglia are like floor managers inspecting the kitchen. If a burner is broken, unsafe, or no longer needed, they mark it for removal. That is useful when the managers are accurate.

But problems arise if the managers become overzealous.

If they start removing equipment that still works, the kitchen loses capacity. The chefs may still be skilled, but they now have fewer burners, fewer workstations, and fewer ways to coordinate orders. Service slows down. Mistakes increase. Eventually, whole sections stop functioning.

Biologically, the article focuses on complement-related pruning, involving molecules such as C1q and C3, which can tag synapses for removal. In normal conditions, this system helps regulate neural circuits. But if the tagging or pruning becomes excessive, useful synaptic connections may be lost.

The article connects this idea to ALS by suggesting that overactive pruning could weaken motor circuits and possibly circuits involved in mood, behavior, and cognition as well.

Mitochondria: The Restaurant’s Power System

Mitochondria are often called the power plants of the cell. For neurons, they are especially important because neurons have enormous energy demands.

Neurons must fire electrical signals, maintain long axons, recycle neurotransmitters, repair damage, and preserve synaptic connections. Motor neurons are particularly vulnerable because many of them are large, highly active cells with long projections reaching from the spinal cord to distant muscles.

In the restaurant analogy, mitochondria are the electrical system that keeps the lights, ovens, refrigerators, ventilation, and cash registers running.

If demand rises but the power supply cannot keep up, the restaurant begins to fail. Maybe the refrigerators still work, but the ovens heat unevenly. Maybe one station shuts down during the dinner rush. Maybe the ventilation fails and the kitchen becomes unsafe.

The article argues that in ALS, mitochondrial weakness may make certain circuits less able to withstand stress. If microglial pruning increases, excitatory signaling rises, inflammation persists, and aging reduces resilience, the mitochondria must work harder. When they cannot meet demand, circuit function begins to deteriorate.

The article also notes that mitochondrial structural and functional abnormalities have been observed in ALS-related tissues, including spinal cord and muscle.

NAD+: The Backup Battery and Cooling Fluid

NAD+ — nicotinamide adenine dinucleotide — sounds technical, but its role can be explained simply.

If mitochondria are the power plant, then NAD+ is like a combination of fuel additive, backup battery, and cooling system. It helps cells produce energy, manage oxidative stress, support DNA repair, and regulate important metabolism-related proteins such as sirtuins.

As people age, NAD+ levels tend to decline. In the restaurant analogy, this is like an old backup generator losing efficiency. It may still help during minor power problems, but it cannot rescue the system forever.

The article proposes that NAD+ may temporarily compensate when mitochondrial energy production becomes strained. In early stages, this reserve may help a vulnerable circuit keep functioning. But if stress continues, NAD+ reserves may become depleted.

Once that happens, a circuit that was barely holding on may shift toward more obvious failure.

However, the article is careful here: this remains a hypothesis. The role of NAD+ in ALS progression is not yet proven in large clinical datasets, and the article does not establish NAD+ supplementation as a treatment.

Autophagy: The Cleanup Crew

Every busy restaurant produces waste. Food scraps, grease, broken packaging, spoiled ingredients, and damaged tools all need to be removed. If the cleaning crew works every day, the kitchen stays usable. If trash piles up for a week, the restaurant becomes chaotic and unsafe.

Cells have a similar cleanup system called autophagy.

Autophagy helps identify, package, break down, and recycle damaged proteins, worn-out mitochondria, and other cellular waste. Neurons depend heavily on this process because they are long-lived cells and cannot simply dilute waste by dividing frequently.

In ALS research, several genes linked to autophagy or protein clearance — including TBK1, OPTN, and C9orf72 — are already associated with ALS risk.

The article places autophagy failure into the larger model as a key factor determining whether a stressed neural circuit can recover or collapses. If the cleanup crew is still functioning, the circuit may survive under pressure. If cleanup fails, damaged proteins and mitochondria accumulate, energy production worsens, inflammation may increase, and the system becomes more fragile.

In restaurant terms: once the trash blocks the walkways, the chefs cannot work, the equipment overheats, pests arrive, and the kitchen may be forced to close.

Three Circuit States: From Compensation to Collapse

One of the article’s central ideas is a three-stage model of neural circuit vulnerability.

These stages are not necessarily whole-body stages. Instead, they describe the state of individual circuits.

1. Compensated Plasticity

This is the “still managing” stage.

The restaurant is understaffed and under pressure, but experienced workers are covering extra shifts. Backup supplies are being used. Customers may not notice much yet.

In ALS, this could correspond to very subtle symptoms:

• occasional hand stiffness;
• mild fatigue;
• slight clumsiness;
• intermittent speech changes;
• mood or motivation changes that are easy to dismiss.

The system is stressed, but it still has enough reserve to compensate.

2. Fragile Plasticity

This is the “clearly struggling” stage.

A few burners are down. Orders are delayed. Some dishes come out wrong. Staff members are still trying to compensate, but the restaurant is unstable.

Clinically, this may correspond to more definite symptoms:

• progressive limb weakness;
• worsening fine motor control;
• clearer speech or swallowing difficulty;
• increasing fatigue;
• emotional, behavioral, or cognitive changes.

At this point, the circuit has not fully collapsed, but it is vulnerable. A further increase in stress or loss of reserve may push it over the edge.

3. Network Collapse

This is the shutdown stage.

The power fails, the cleaning system is overwhelmed, backup supplies are gone, and managers can no longer maintain order. The restaurant cannot function.

In ALS, the article suggests this state may correspond to rapid functional decline, sharp worsening of affected abilities, and possibly rising biomarkers of neural injury, such as neurofilament light chain, or NfL.

NfL is a blood or cerebrospinal fluid marker associated with nerve cell injury. In this model, a major rise in NfL would be expected when circuits move from fragile instability into collapse.

Why ALS Looks Different in Different People

A key point is that these stages may occur asynchronously.

In other words, a person’s hand-control circuit might already be in collapse, while their breathing circuit is still fragile and their cognitive circuits remain compensated. Another person may have early bulbar involvement — speech and swallowing — while limb function remains relatively preserved for a time.

This is one of the most useful parts of the framework. It gives a possible explanation for why ALS is so variable.

Instead of asking only, “How advanced is this person’s ALS?” the model encourages more precise questions:

• Which neural circuits are under the most stress?
• Which circuits still have reserve?
• Is the energy system failing?
• Is autophagy still working?
• Is microglial pruning excessive?
• Are inflammation and aging reducing resilience?
• Which symptoms reflect compensation, fragility, or collapse?

This is what the article means by a more symptom-level or circuit-level approach to ALS.

ALS and FTD: Related, But Not Identical

The article also discusses the relationship between ALS and frontotemporal dementia, or FTD.

ALS and FTD are biologically connected. Some patients with ALS also meet criteria for FTD, and many more show milder cognitive or behavioral changes. Both conditions can involve overlapping genes and molecular pathways, including C9orf72-related disease.

However, the article argues that ALS and FTD may not simply be the same disease appearing in different locations. They may involve partly different biological failure patterns.

Using transcriptome-wide association study, or TWAS, methods, the article suggests that ALS and FTD may diverge along certain pathways. For example, the article describes ALS as being associated with increased PI3K-AKT-mTOR pathway activity and reduced mitochondrial energy capacity, while FTD may involve insufficient PGC-1α-mediated mitochondrial biogenesis and weakened SIRT1-related metabolism.

Put more simply: ALS and FTD may share the same broad neighborhood, but the “restaurant failures” may not be identical. In ALS, one section of the kitchen may be overheating while losing power. In FTD, another section may fail because it cannot build enough new energy capacity or maintain metabolic regulation.

If future research confirms this, it could matter for treatment. A therapy that helps one failure pattern may not automatically help the other.

What This Means for Treatment — and What It Does Not Mean

The article is not presenting a new ALS treatment.

That distinction is important.

Current disease-modifying treatments for ALS remain limited. Riluzole has long-standing clinical trial support. Edaravone has evidence for benefit in a more specific group of patients. Tofersen is a precision therapy for ALS associated with SOD1 mutations. AMX0035, also known as Relyvrio, was voluntarily withdrawn from the market after its phase 3 trial failed to confirm benefit.

This history is a reminder that a strong biological idea is not enough. ALS has seen many promising theories that did not translate into successful treatments in large trials.

The Cureus article presents a hypothesis framework. It is meant to guide research questions, not to tell patients what supplements or medications to take.

In particular, the discussion of NAD+ should not be interpreted as proof that NAD+ boosters treat ALS. The article itself does not provide that kind of clinical evidence.

Testable Predictions

A strength of the framework is that it makes predictions that could be tested.

For example, if the model is correct, then rising NfL should correlate especially strongly with the transition from fragile plasticity to network collapse, rather than simply tracking general disability scores.

Another prediction is that cell models carrying ALS-associated variants such as TBK1 or C9orf72 may show faster NAD+ depletion and autophagy impairment when exposed to simulated pruning or inflammatory stress.

These are useful scientific predictions because they can be checked. If the predictions fail, the framework would need to be revised or possibly rejected.

That is how a good hypothesis should work: it should be interesting, but also vulnerable to being proven wrong.

Why the Article Matters

For general readers, the article’s value is not that it solves ALS. It does not.

Its value is that it offers a different way to think about the disease.

Instead of treating ALS as one uniform process, the article asks us to imagine many different circuits, each with its own balance of stress and reserve. One person’s disease may begin where microglial pruning pressure overwhelms a vulnerable motor circuit. Another person’s symptoms may reflect early energy failure in bulbar circuits. Another may show more cognitive or behavioral involvement because frontal or temporal networks are under stress.

This kind of thinking could eventually help researchers design more precise clinical trials. Rather than grouping all ALS patients together, future studies might separate people by biomarkers, symptom pattern, genetic background, mitochondrial function, inflammatory state, autophagy capacity, or rate of NfL change.

That could make it easier to detect whether a treatment is helping the subgroup it is actually designed to help.

Important Limitations

The article is also clear that the framework remains preliminary.

Several limitations matter:

• Much of the framework is built on related work by the same researcher.
• Some supporting papers are preprints and have not yet gone through independent peer review.
• TWAS analyses can show associations, but they cannot prove causation.
• Computer simulations can generate hypotheses, but they are not substitutes for patient studies.
• Large longitudinal datasets combining symptoms, imaging, NfL, NAD+ metabolism, autophagy markers, genetics, and inflammatory measures are still needed.

So while the model is intellectually appealing, it should be treated as a research map, not as established clinical truth.

Practical Takeaway for Patients and Families

For patients and families, the safest takeaway is this:

Do not use this article as a reason to start unproven treatments on your own.

That includes NAD+ supplements or combinations aimed at mitochondria, inflammation, or autophagy unless they are discussed with the treating clinician.

ALS care should remain grounded in evidence-based management, including:

• care from an ALS neurologist or neuromuscular specialist;
• multidisciplinary clinic support;
• respiratory monitoring;
• nutrition and swallowing support;
• physical and occupational therapy;
• speech and communication assistance;
• mobility planning;
• psychological and caregiver support;
• appropriate use of approved or evidence-supported therapies.

Research hypotheses are valuable, but they are not the same as medical recommendations.

Bottom Line

This article presents ALS as more than a disease of dying motor neurons. It describes ALS as a possible failure of balance between biological stress and biological reserve.

In the restaurant analogy:

• neurons are the chefs;
• mitochondria are the power supply;
• NAD+ is the backup battery and coolant;
• autophagy is the cleaning and recycling crew;
• microglia are the managers who prune and remove equipment;
• aging and inflammation are the slow wear and tear on the building.

When the system can compensate, symptoms may be subtle. When it becomes fragile, symptoms become clearer. When the network collapses, decline may accelerate.

The framework is promising because it may help explain why ALS varies so much from person to person. But it remains a hypothesis that needs rigorous validation.

For now, it is best understood as a thoughtful map of possible mechanisms — not a finished answer, and not a treatment plan.

Reference:
Cheung N. Symptom-Level Precision Neurology in Amyotrophic Lateral Sclerosis (ALS): Linking Microglial Pruning, Mitochondrial Nicotinamide Adenine Dinucleotide (NAD+) Compensation, and Autophagy Failure Across the Aging Spectrum. Cureus. 2026;18(5):e109147. doi:10.7759/cureus.109147
http://doi.org/10.7759/cureus.109147